Email updates

Keep up to date with the latest news and content from BMC Dermatology and BioMed Central.

Download references

Open Access

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

Kim A Papp*, Darryl Toth and Les Rosoph

BMC Dermatology 2006, 6:9  doi:10.1186/1471-5945-6-9

Include


Format